MCID: MST023
MIFTS: 59

Mesothelioma, Malignant

Categories: Genetic diseases, Rare diseases, Respiratory diseases, Cancer diseases

Aliases & Classifications for Mesothelioma, Malignant

MalaCards integrated aliases for Mesothelioma, Malignant:

Name: Mesothelioma, Malignant 57 53 75 29 44 40
Malignant Mesothelioma 12 53 55 15 73
Advanced Malignant Mesothelioma 12 73
Mesothelioma, Somatic 57 13
Pleural Mesothelioma 59 73
Mesom 57 75
Asbestos-Related Malignant Mesothelioma 12
Diffuse Malignant Mesothelioma 12
Malignant Tumor of Mesothelium 12
Malignant Pleural Mesothelioma 73
Mesothelioma Diffuse Malignant 55
Mesothelioma 73

Characteristics:

Orphanet epidemiological data:

59
pleural mesothelioma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

OMIM:

57
Inheritance:
somatic mutation

Miscellaneous:
etiologically linked to asbestos
may be seen in conjunction with other cancer syndromes (e.g., tdps )


HPO:

32
mesothelioma, malignant:
Inheritance somatic mutation


Classifications:

Orphanet: 59  
Rare respiratory diseases


External Ids:

OMIM 57 156240
Disease Ontology 12 DOID:1790
SNOMED-CT 68 62064005
Orphanet 59 ORPHA50251
UMLS via Orphanet 74 C0025500 C0812413 C1377913
MESH via Orphanet 45 D008654
ICD10 via Orphanet 34 C45.0
MedGen 42 C0345967

Summaries for Mesothelioma, Malignant

NIH Rare Diseases : 53 Malignant mesothelioma is a form of cancer that develops in the thin layer of tissue that surrounds the lungs, chest wall, or abdomen. Signs and symptoms of the condition can vary and often depend on which area of the body is affected. Common features include abdominal bloating, abdominal pain, chest pain, coughing, fatigue, shortness of breath, and/or weight loss. Malignant mesothelioma is thought to be caused by long-term exposure to asbestos (a fire-resistant material that was once commonly found in insulation; ceiling and roof vinyls; cement; and automotive brake materials). Most people appear to be diagnosed with the condition approximately 30 years after being in contact with the asbestos. Unfortunately, there is generally no cure for malignant mesothelioma unless it is diagnosed at an early stage and can be surgically removed. If surgery is not an option, chemotherapy and/or radiation therapy may still be recommended to help alleviate some of the associated symptoms.

MalaCards based summary : Mesothelioma, Malignant, also known as malignant mesothelioma, is related to malignant epithelial mesothelioma and pericardial mesothelioma, and has symptoms including chest pain, dyspnea and fatigue. An important gene associated with Mesothelioma, Malignant is BCL10 (B Cell CLL/Lymphoma 10), and among its related pathways/superpathways are Cytoskeletal Signaling and MicroRNAs in cancer. The drugs Alimta and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and liver, and related phenotypes are pleural effusion and weight loss

OMIM : 57 Malignant mesothelioma is an aggressive neoplasm of the serosal lining of the chest etiologically linked to asbestos. It is diagnosed in approximately 2,000 to 3,000 individuals annually in the United States, most of whom die within 2 years of diagnosis (summary by Bott et al., 2011). See also 614327 for a tumor predisposition syndrome that may contribute to the development of malignant mesothelioma upon asbestos exposure and is caused by germline mutation in the BAP1 gene (603089) on chromosome 3p21. (156240)

UniProtKB/Swiss-Prot : 75 Mesothelioma, malignant: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos.

Disease Ontology : 12 A cell type cancer that has material basis in mesothelial tissue.

Related Diseases for Mesothelioma, Malignant

Diseases in the Benign Mesothelioma family:

Mesothelioma, Malignant Benign Intermediate Mesothelioma

Diseases related to Mesothelioma, Malignant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
# Related Disease Score Top Affiliating Genes
1 malignant epithelial mesothelioma 33.7 THBD WT1
2 pericardial mesothelioma 32.7 KRT7 MUC1 THBD
3 malignant biphasic mesothelioma 32.5 KRT7 THBD WT1
4 peritoneal mesothelioma 32.3 BAP1 CDKN2A MUC1 NF2 THBD WT1
5 sarcomatoid mesothelioma 31.8 CDKN2A MUC1 NKX2-1 THBD WT1
6 malignant pleural mesothelioma 31.6 BAP1 CDH2 MUC1 NKX2-1 SPP1 THBD
7 malignant peritoneal mesothelioma 31.6 BAP1 CDKN2A MUC1 NF2
8 adenomatoid tumor 30.5 KRT7 THBD WT1
9 renal cell carcinoma, nonpapillary 28.4 CDH1 KRT7 MIR584 MUC1 NKX2-1 RASSF1
10 ovarian malignant mesothelioma 12.0
11 fallopian tube squamous cell carcinoma 11.1 CDKN2A WT1
12 psammomatous meningioma 11.0 CTNNB1 NF2
13 gallbladder adenoma 11.0 CDKN2A CTNNB1
14 optic nerve sheath meningioma 11.0 CDKN2A NF2
15 inverted transitional papilloma 10.9 CDKN2A KRT7
16 parasagittal meningioma 10.9 CDH1 NF2
17 melanomatosis 10.9 CDKN2A WT1
18 renal adenoma 10.9 KRT7 WT1
19 cerebral convexity meningioma 10.8 CDH1 NF2
20 female reproductive endometrioid cancer 10.8 CTNNB1 KRT7 WT1
21 fibrous meningioma 10.8 MUC1 NF2
22 lymphohistiocytoid mesothelioma 10.8 CDKN2A THBD
23 transitional meningioma 10.8 MUC1 NF2
24 papillary craniopharyngioma 10.8 CTNNB1 KRT7
25 neurofibroma 10.8 CDKN2A MUC1 NF2
26 ovarian germ cell teratoma 10.8 KRT7 NKX2-1
27 organ system benign neoplasm 10.8 CTNNB1 KRT7 NF2
28 acinar cell carcinoma 10.7 BCL10 CTNNB1 KRT7
29 small cell carcinoma of the bladder 10.7 KRT7 NKX2-1
30 ovarian germ cell cancer 10.7 KRT7 NKX2-1
31 malignant peripheral nerve sheath tumor 10.7 CDKN2A MUC1 NF2
32 cell type benign neoplasm 10.7 CDKN2A CTNNB1 KRT7
33 epithelial predominant wilms' tumor 10.7 KRT7 WT1
34 chordoid glioma 10.7 MUC1 NF2 NKX2-1
35 parachordoma 10.7 KRT7 MUC1
36 bile duct mucoepidermoid carcinoma 10.7 KRT7 MUC1
37 middle ear adenoma 10.7 KRT7 MUC1
38 endosalpingiosis 10.7 KRT7 MUC1 WT1
39 lung acinar adenocarcinoma 10.7 CTNNB1 KRT7 NKX2-1
40 ovarian brenner tumor 10.7 KRT7 THBD WT1
41 cystitis cystica 10.7 CTNNB1 KRT7 THBD
42 pulmonary sclerosing hemangioma 10.7 CTNNB1 KRT7 NKX2-1
43 epstein-barr virus-associated gastric carcinoma 10.7 CDH1 CDKN2A CTNNB1
44 goblet cell carcinoid 10.7 CDH1 CTNNB1
45 sertoli-leydig cell tumor 10.7 KRT7 MUC1 WT1
46 endocervical carcinoma 10.7 CDKN2A KRT7
47 adenomyoma 10.7 CTNNB1 KRT7 MUC1
48 secretory meningioma 10.6 KRT7 MUC1 NF2
49 well-differentiated liposarcoma 10.6 CDKN2A KRT7 MUC1
50 linitis plastica 10.6 CDH1 KRT7

Graphical network of the top 20 diseases related to Mesothelioma, Malignant:



Diseases related to Mesothelioma, Malignant

Symptoms & Phenotypes for Mesothelioma, Malignant

Symptoms via clinical synopsis from OMIM:

57
Respiratory Lung:
mesothelioma, malignant

Neoplasia:
mesothelioma


Clinical features from OMIM:

156240

Human phenotypes related to Mesothelioma, Malignant:

59 32 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pleural effusion 59 32 hallmark (90%) Very frequent (99-80%) HP:0002202
2 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
3 respiratory distress 59 32 frequent (33%) Frequent (79-30%) HP:0002098
4 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
5 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
6 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
7 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
8 lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002716
9 fourth cranial nerve palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0007011
10 abnormality of cardiovascular system physiology 59 32 occasional (7.5%) Occasional (29-5%) HP:0011025
11 obstruction of the superior vena cava 59 32 occasional (7.5%) Occasional (29-5%) HP:0031041
12 abnormality of the thorax 59 Frequent (79-30%)
13 dyspnea 59 Frequent (79-30%)
14 abnormality of the pleura 59 Frequent (79-30%)
15 constitutional symptom 59 Frequent (79-30%)
16 abnormality of lung morphology 59 Occasional (29-5%)
17 functional respiratory abnormality 59 Occasional (29-5%)
18 malignant mesothelioma 32 HP:0100001

UMLS symptoms related to Mesothelioma, Malignant:


chest pain, dyspnea, fatigue, chills, malaise

MGI Mouse Phenotypes related to Mesothelioma, Malignant:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 BAP1 BCL10 CDH1 CDH2 CDKN2A CTNNB1
2 cardiovascular system MP:0005385 10.18 BAP1 CDH1 CDH2 CDKN2A CTNNB1 NKX2-1
3 homeostasis/metabolism MP:0005376 10.1 BAP1 CDH1 CDH2 CDKN2A CTNNB1 KRT7
4 embryo MP:0005380 10.06 BAP1 BCL10 CDH1 CDH2 CDKN2A CTNNB1
5 endocrine/exocrine gland MP:0005379 10.02 CTNNB1 NF2 NKX2-1 RASSF1 WT1 BAP1
6 digestive/alimentary MP:0005381 9.98 RASSF1 THBD BAP1 CDH1 CDKN2A CTNNB1
7 neoplasm MP:0002006 9.81 BAP1 CDH1 CDKN2A CTNNB1 NF2 NKX2-1
8 liver/biliary system MP:0005370 9.8 CDKN2A CTNNB1 NF2 RASSF1 SPP1 THBD
9 reproductive system MP:0005389 9.61 CDKN2A CTNNB1 NF2 NKX2-1 SPP1 THBD
10 respiratory system MP:0005388 9.23 BAP1 CDKN2A CTNNB1 NF2 NKX2-1 SPP1

Drugs & Therapeutics for Mesothelioma, Malignant

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004

Drugs for Mesothelioma, Malignant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 292)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
3
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
4
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Hydroxocobalamin Approved Phase 2, Phase 3,Phase 3 13422-51-0 11953898 44475014
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
8
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
9
Vorinostat Approved, Investigational Phase 3,Phase 1,Phase 2 149647-78-9 5311
10
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
11
Raltitrexed Approved, Investigational Phase 3,Phase 2,Phase 1 112887-68-0 104758
12
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
13
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
16
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
17
Nintedanib Approved Phase 3,Phase 2,Phase 1 656247-17-5 56843413
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
20
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 68-19-9 44176380
21
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 13422-55-4
22
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
23 Ranpirnase Investigational Phase 3 196488-72-9
24 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
25 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
27 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
28 Alkylating Agents Phase 3,Phase 2,Phase 1
29 Antimitotic Agents Phase 3,Phase 2,Phase 1
30 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
31 Mitomycins Phase 3,Phase 2
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
33 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
34 Vitamin B Complex Phase 3,Phase 2,Phase 1
35 Antimetabolites Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Analgesics Phase 3,Phase 2,Phase 1
38 Antiemetics Phase 3,Phase 2,Phase 1
39 Vitamin B 12 Phase 2, Phase 3,Phase 3
40 Vitamins Phase 2, Phase 3,Phase 3,Phase 1
41 Autonomic Agents Phase 3,Phase 2,Phase 1
42 BB 1101 Phase 3,Phase 2,Phase 1
43 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
44 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
45 Micronutrients Phase 3,Phase 2,Phase 1
46 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
47 Trace Elements Phase 3,Phase 2,Phase 1
48 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
49 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 380)
# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) Completed NCT00128102 Phase 3 vorinostat;Placebo
3 Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
4 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
5 Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Completed NCT00004920 Phase 3 cisplatin;raltitrexed
6 A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
7 Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma Completed NCT00006231 Phase 3
8 Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma Completed NCT00821860 Phase 3
9 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
10 Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
11 Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma Recruiting NCT03063450 Phase 3 Nivolumab
14 Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
15 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
16 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Active, not recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
17 Nintedanib (BIBF 1120) in Mesothelioma Active, not recruiting NCT01907100 Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
18 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
19 PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Terminated NCT01604005 Phase 3
20 Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication Withdrawn NCT02511600 Phase 3
21 A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma Unknown status NCT01649024 Phase 2 Tremelimumab
22 An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma Unknown status NCT00685204 Phase 2 Milataxel
23 The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma Unknown status NCT01655888 Phase 2 Tremelimumab
24 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
25 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
26 A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
27 Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma Unknown status NCT00030459 Phase 2 cisplatin;mitomycin C;vinblastine sulfate;vinorelbine tartrate
28 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
29 Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
30 Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
31 Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma Unknown status NCT01358084 Phase 2 NGR-hTNF;Placebo
32 Sorafenib in Previously Treated Malignant Mesothelioma Unknown status NCT00794859 Phase 2 Sorafenib
33 Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
34 A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
35 Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma Unknown status NCT01281800 Phase 2
36 A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
37 High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma Unknown status NCT00002465 Phase 1, Phase 2 megestrol acetate
38 Four Versus Six Cycles of Pemetrexed/Platinum for MPM Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
39 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
40 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
41 Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients Unknown status NCT01134250 Phase 1, Phase 2 F16IL2 in combination with paclitaxel
42 Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma Unknown status NCT01959438 Phase 1, Phase 2 Sodium selenite (Introselen);Sodium selenite
43 Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis Unknown status NCT00454519 Phase 2
44 Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
45 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed NCT01024946 Phase 2 everolimus
46 Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00386815 Phase 2 pemetrexed;cisplatin
47 Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment Completed NCT01243632 Phase 2 Prolonged 6-hr infusion of gemcitabine
48 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Completed NCT01160458 Phase 2 IMC-A12
49 An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma Completed NCT00787410 Phase 2 ZD1839
50 Tomotherapy Treatment for Mesothelioma Completed NCT00469196 Phase 2

Search NIH Clinical Center for Mesothelioma, Malignant

Cochrane evidence based reviews: mesothelioma, malignant

Genetic Tests for Mesothelioma, Malignant

Genetic tests related to Mesothelioma, Malignant:

# Genetic test Affiliating Genes
1 Mesothelioma, Malignant 29 BCL10 WT1

Anatomical Context for Mesothelioma, Malignant

MalaCards organs/tissues related to Mesothelioma, Malignant:

41
Lung, T Cells, Liver, Pancreas, Kidney, Endothelial, Myeloid

Publications for Mesothelioma, Malignant

Articles related to Mesothelioma, Malignant:

# Title Authors Year
1
MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function. ( 24444362 )
2014
2
A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. ( 17108115 )
2006
3
Biphasic malignant mesothelioma (malignant adenomatoid tumor) of paratesticular tissue. ( 6740857 )
1984

Variations for Mesothelioma, Malignant

ClinVar genetic disease variations for Mesothelioma, Malignant:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 WT1 NM_024426.4(WT1): c.1021A> G (p.Ser341Gly) single nucleotide variant Pathogenic rs121907908 GRCh38 Chromosome 11, 32400025: 32400025
2 WT1 NM_024426.4(WT1): c.1021A> G (p.Ser341Gly) single nucleotide variant Pathogenic rs121907908 GRCh37 Chromosome 11, 32421571: 32421571
3 BCL10 NM_003921.4(BCL10): c.499_500insT (p.Ser167Phefs) insertion Pathogenic rs387906350 GRCh37 Chromosome 1, 85733513: 85733513
4 BCL10 NM_003921.4(BCL10): c.499_500insT (p.Ser167Phefs) insertion Pathogenic rs387906350 GRCh38 Chromosome 1, 85267830: 85267830
5 BCL10 NM_003921.4(BCL10): c.136delA (p.Ile46Tyrfs) deletion Pathogenic rs587776639 GRCh37 Chromosome 1, 85736511: 85736511
6 BCL10 NM_003921.4(BCL10): c.136delA (p.Ile46Tyrfs) deletion Pathogenic rs587776639 GRCh38 Chromosome 1, 85270828: 85270828

Copy number variations for Mesothelioma, Malignant from CNVD:

7 (show all 35)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13405 1 1 2300000 Loss Malignant mesothelioma
2 21838 1 16200000 28000000 Loss Malignant mesothelioma
3 33950 1 50700000 61300000 Amplification Malignant mesothelioma
4 35952 1 69700000 116100000 Loss Malignant mesothelioma
5 35954 1 69700000 116100000 Loss CLCA1 Malignant mesothelioma
6 35956 1 69700000 116100000 Loss CLCA2 Malignant mesothelioma
7 35958 1 69700000 116100000 Loss CLCA3 Malignant mesothelioma
8 35960 1 69700000 116100000 Loss CLCA4 Malignant mesothelioma
9 35962 1 69700000 116100000 Loss COL11A1 Malignant mesothelioma
10 35964 1 69700000 116100000 Loss TGFBR3 Malignant mesothelioma
11 35966 1 69700000 120600000 Loss Malignant mesothelioma
12 37056 1 84900000 107200000 Loss Malignant mesothelioma
13 69952 12 56600000 58100000 Gain Malignant mesothelioma
14 75172 13 17900000 45800000 Loss BRCA2 Malignant mesothelioma
15 85738 14 50900000 107349540 Loss CCNK Malignant mesothelioma
16 85740 14 50900000 107349540 Loss CDKN3 Malignant mesothelioma
17 113645 17 44900000 81195210 Gain ERN1 Malignant mesothelioma
18 113647 17 44900000 81195210 Gain MAP3K3 Malignant mesothelioma
19 113649 17 44900000 81195210 Gain PRKCA Malignant mesothelioma
20 113651 17 44900000 81195210 Gain SMARCD2 Malignant mesothelioma
21 175422 3 39400000 63700000 Loss CACNA2D3 Malignant mesothelioma
22 175424 3 39400000 63700000 Loss CTNNB1 Malignant mesothelioma
23 175426 3 39400000 63700000 Loss MLH1 Malignant mesothelioma
24 175771 3 44100000 44200000 Loss Malignant mesothelioma
25 187512 4 50400000 191154276 Loss Malignant mesothelioma
26 191705 5 1 48400000 Gain Malignant mesothelioma
27 204729 6 114600000 118300000 Loss HDAC2 Malignant mesothelioma
28 204731 6 114600000 118300000 Loss MARCKS Malignant mesothelioma
29 217075 7 1 4500000 Gain Malignant mesothelioma
30 234871 8 139900000 146364022 Gain Malignant mesothelioma
31 250026 9 19900000 25600000 Loss C9orf14 Malignant mesothelioma
32 250029 9 19900000 25600000 Loss CDKN2A Malignant mesothelioma
33 250031 9 19900000 25600000 Loss CDKN2B Malignant mesothelioma
34 250069 9 19900000 33200000 Loss Malignant mesothelioma
35 251883 9 33200000 36300000 Gain Malignant mesothelioma

Expression for Mesothelioma, Malignant

Search GEO for disease gene expression data for Mesothelioma, Malignant.

Pathways for Mesothelioma, Malignant

GO Terms for Mesothelioma, Malignant

Cellular components related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell-cell adherens junction GO:0005913 9.61 CDH1 CDH2 CTNNB1
2 apical part of cell GO:0045177 9.58 CDH2 CTNNB1 NF2
3 adherens junction GO:0005912 9.54 CDH2 CTNNB1 NF2
4 lamellipodium GO:0030027 9.46 CDH1 CDH2 CTNNB1 NF2
5 fascia adherens GO:0005916 9.32 CDH2 CTNNB1
6 flotillin complex GO:0016600 9.26 CDH1 CTNNB1
7 cortical actin cytoskeleton GO:0030864 9.13 CDH1 CDH2 NF2
8 catenin complex GO:0016342 8.8 CDH1 CDH2 CTNNB1

Biological processes related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.65 BAP1 CDKN2A CTNNB1 NF2 WT1
2 epithelial tube branching involved in lung morphogenesis GO:0060441 9.43 CTNNB1 NKX2-1
3 negative regulation of cell-cell adhesion GO:0022408 9.4 CDH1 NF2
4 ectoderm development GO:0007398 9.37 CTNNB1 NF2
5 entry of bacterium into host cell GO:0035635 9.32 CDH1 CTNNB1
6 positive regulation of transcription, DNA-templated GO:0045893 9.17 BCL10 CDH1 CDKN2A CTNNB1 NKX2-1 SPP1
7 cellular response to indole-3-methanol GO:0071681 9.16 CDH1 CTNNB1
8 adherens junction organization GO:0034332 9.13 CDH1 CDH2 CTNNB1

Molecular functions related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoskeletal protein binding GO:0008092 9.33 CDH1 CDH2 NF2
2 alpha-catenin binding GO:0045294 8.96 CDH2 CTNNB1
3 gamma-catenin binding GO:0045295 8.62 CDH1 CDH2

Sources for Mesothelioma, Malignant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....